In preclinical models, the activation of the PI3K-AKT signaling pathway has been observed to synergize with alterations, such as the expression of the BRAFV600E oncoprotein kinase, to promote melanoma progression and metastasis [194]. The gene discussed is AKT1; the disease is melanoma.